Patent: 9,056,915
✉ Email this page to a colleague
Summary for Patent: 9,056,915
Title: | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
Abstract: | Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. |
Inventor(s): | Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY) |
Assignee: | Amgen Inc. (Thousand Oaks, CA) |
Application Number: | 14/459,768 |
Patent Claims: | see list of patent claims |
Details for Patent 9,056,915
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen Inc. | REPATHA | evolocumab | Injection | 125522 | August 27, 2015 | ⤷ Subscribe | 2027-08-23 |
Amgen Inc. | REPATHA | evolocumab | Injection | 125522 | July 08, 2016 | ⤷ Subscribe | 2027-08-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,056,915
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2009026558 | ⤷ Subscribe |
United States of America | 9920134 | ⤷ Subscribe |
United States of America | 9493576 | ⤷ Subscribe |
United States of America | 9045547 | ⤷ Subscribe |
United States of America | 8981064 | ⤷ Subscribe |
United States of America | 8889834 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |